Vnitr Lek 2021, 67(7):426-432 | DOI: 10.36290/vnl.2021.111

Appropriate and inappropriate therapies of implantable cardioverter‑defibrillators

David Kiss1, 2, Milan Kozák1, 2, Milan Sepši1, 2, Petr Kala1, 2
1 Interní kardiologická klinika, Fakultní nemocnice Brno
2 Interní kardiologická klinika, Lékařská fakulta Masarykovy univerzity

Implantable cardioverter-defibrillators (ICD) reduce mortality of patients with risk of sudden cardiac death in primary and secondary prevention. Patients with implanted ICD can receive appropriate and inappropriate therapies with different incidence in both indication groups. There are some factors which can predict the incidence of ICD therapies. In some cases higher incidence of ICD therapies could negatively impact quality of patients lives. As predictive factors for higher incidence of appropriate therapies are discussed: reduced left venctricular ejection fraction, body mass index, chronic renal failure and frequent hospitalization for acute decompensation of chronic heart failure. As predictive factors for higher incidence of inappropriate therapies are discussed supraventricular tachycardia in patients history and single-chamber implantable kardioverter-defibrillator. The article summarizes indication criteria, incidence, predictive factors and treatment of appropriate and inappropriate therapies.

Keywords: appropriate therapy, implantable cardioverter‑defibrillator, inappropriate therapy, sudden cardiac death.

Published: November 1, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Kiss D, Kozák M, Sepši M, Kala P. Appropriate and inappropriate therapies of implantable cardioverter‑defibrillators. Vnitr Lek. 2021;67(7):426-432. doi: 10.36290/vnl.2021.111.
Download citation

References

  1. Kozák M. [Therapy with implantable cardioverter‑defibrillators (ICD) in the early of third millenium]. Vnitr Lek 2010; 56(8): 860-864. Go to PubMed...
  2. Bardy GH, Lee KL, Mark DB et al. Amiodarone or an Implantable Cardioverter-Defibrillator for Congestive Heart Failure. N Engl J Med 2005; 352(3): 225-237. doi:10.1056/NEJMoa043399 Go to original source... Go to PubMed...
  3. Priori SG, Blomström‑Lundqvist C, Mazzanti A et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC)Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J 2015; 36(41): 2793-2867. doi:10.1093/eurheartj/ehv316 Go to original source... Go to PubMed...
  4. Sweeney MO, Wathen MS, Volosin K et al. Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial. Circulation 2005; 111(22): 2898-2905. doi:10.1161/CIRCULATIONAHA.104.526673 Go to original source... Go to PubMed...
  5. Weeke P, Johansen JB, Jorgensen OD et al. Mortality and appropriate and inappropriate therapy in patients with ischaemic heart disease and implanted cardioverter‑defibrillators for primary prevention: data from the Danish ICD Register. Europace 2013; 15(8): 1150-1157. doi:10.1093/europace/eut017 Go to original source... Go to PubMed...
  6. Boulé S, Sémichon M, Guédon‑Moreau L et al. Long‑term outcome of implantable cardioverter-defibrillator implantation in secondary prevention of sudden cardiac death. Arch Cardiovasc Dis 2016; 109(10): 517-526. doi:10.1016/j.acvd.2016. 02. 008 Go to original source... Go to PubMed...
  7. Moss AJ, Hall WJ, Cannom DS et al. Cardiac‑Resynchronization Therapy for the Prevention of Heart‑Failure Events. N Engl J Med 2009; 361(14): 1329-1338. doi:10.1056/NEJMoa0906431 Go to original source... Go to PubMed...
  8. Ruwald AC, Vinther M, Gislason GH et al. The impact of co‑morbidity burden on appropriate implantable cardioverter defibrillator therapy and all‑cause mortality: insight from Danish nationwide clinical registers: ICD implantation and co‑morbidities. Eur J Heart Fail 2017; 19(3): 377-386. doi:10.1002/ejhf.685 Go to original source... Go to PubMed...
  9. Greenlee RT, Go AS, Peterson PN et al. Device Therapies Among Patients Receiving Primary Prevention Implantable Cardioverter-Defibrillators in the Cardiovascular Research Network. J Am Heart Assoc 2018; 7(7). doi:10.1161/JAHA.117.008292 Go to original source... Go to PubMed...
  10. Providência R, Marijon E, Lambiase PD et al. Primary Prevention Implantable Cardioverter Defibrillator (ICD) Therapy in Women-Data From a Multicenter French Registry. J Am Heart Assoc 2016; 5(2). doi:10.1161/JAHA.115.002756 Go to original source... Go to PubMed...
  11. Schaer B, Kühne M, Reichlin T, Osswald S, Sticherling C. Incidence of and predictors for appropriate implantable cardioverter‑defibrillator therapy in patients with a secondary preventive implantable cardioverter‑defibrillator indication. Europace 2016; 18(2): 227-231. doi:10.1093/europace/euv188 Go to original source... Go to PubMed...
  12. Sapp JL, Wells GA, Parkash R et al. Ventricular Tachycardia Ablation versus Escalation of Antiarrhythmic Drugs. N Engl J Med 2016; 375(2): 111-121. doi:10.1056/NEJMoa1513614 Go to original source... Go to PubMed...
  13. Sweeney MO, Wathen MS, Volosin K et al. Appropriate and Inappropriate Ventricular Therapies, Quality of Life, and Mortality Among Primary and Secondary Prevention Implantable Cardioverter Defibrillator Patients: Results From the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) Trial. Circulation 2005; 111(22): 2898-2905. doi:10.1161/CIRCULATIONAHA.104.526673 Go to original source... Go to PubMed...
  14. Tompkins CM, Mcnitt S, Polonsky B et al. Sex Differences in Inappropriate ICD Device Therapies: MADIT‑II and MADIT‑CRT: Sex Differences in Inappropriate ICD Device Therapies. J Cardiovasc Electrophysiol 2017; 28(1): 94-102. doi:10.1111/jce.13102 Go to original source... Go to PubMed...
  15. Ahmed I, Nelson WB, House CM, Zhu DW. Predictors of appropriate therapy in patients with implantable cardioverter‑defibrillator for primary prevention of sudden cardiac death. Heart Int 2010; 5(1): e4. doi:10.4081/hi.2010.e4 Go to original source... Go to PubMed...
  16. Wu KC, Wongvibulsin S, Tao S et al. Baseline and Dynamic Risk Predictors of Appropriate Implantable Cardioverter Defibrillator Therapy. J Am Heart Assoc 2020; 9(20). doi:10.1161/JAHA.120.017002 Go to original source... Go to PubMed...
  17. Moss AJ, Schuger C, Beck CA et al. Reduction in Inappropriate Therapy and Mortality through ICD Programming. N Engl J Med 2012; 367(24): 2275-2283. doi:10.1056/NEJMoa1211107 Go to original source... Go to PubMed...
  18. Biffi M. ICD programming. Indian Heart J 2014; 66: S88-S100. doi:10.1016/j.ihj.2013. 11. 007 Go to original source... Go to PubMed...
  19. Schwab JO, Bonnemeier H, Kleemann T et al. Reduction of inappropriate ICD therapies in patients with primary prevention of sudden cardiac death: DECREASE study. Clin Res Cardiol 2015; 104(12):1021-1032. doi:10.1007/s00392-015-0870-z Go to original source... Go to PubMed...
  20. Burger AL, Schmidinger H, Ristl R, Pezawas T. Appropriate and inappropriate therapy in patients with single- or multi‑chamber implantable cardioverter‑defibrillators. Hellenic J Cardiol. Published online April 2020:S1109966620300609. doi:10.1016/j.hjc.2020. 03. 001 Go to original source...
  21. Hu Z‑Y, Zhang J, Xu Z‑T et al. Efficiencies and Complications of Dual Chamber versus Single Chamber Implantable Cardioverter Defibrillators in Secondary Sudden Cardiac Death Prevention: A Meta‑analysis. Heart Lung Circ 2016; 25(2):148-154. doi:10.1016/j.hlc.2015. 07. 008 Go to original source...
  22. Kronborg MB, Johansen JB, Haarbo J et al. Association between implantable cardioverter‑defibrillator therapy and different lead positions in patients with cardiac resynchronization therapy. EP Eur 2018; 20(9): e133-e139. doi:10.1093/europace/eux296 Go to original source... Go to PubMed...
  23. Zarse M, Bogossian H, Lemke B. Elektrischer Sturm bei ICD‑Patienten: Prävention und Behandlung. Herzschrittmachertherapie Elektrophysiologie. 2014; 25(2): 66-72. doi:10.1007/s00399-014-0307-9 Go to original source... Go to PubMed...
  24. Parkash R, Nault I, Rivard L et al. Effect of Baseline Antiarrhythmic Drug on Outcomes With Ablation in Ischemic Ventricular Tachycardia: A VANISH Substudy (Ventricular Tachycardia Ablation Versus Escalated Antiarrhythmic Drug Therapy in Ischemic Heart Disease). Circ Arrhythm Electrophysiol. 2018; 11(1). doi:10.1161/CIRCEP.117.005663 Go to original source... Go to PubMed...
  25. Kuck K‑H, Schaumann A, Eckardt L et al. Catheter ablation of stable ventricular tachycardia before defibrillator implantation in patients with coronary heart disease (VTACH): a multicentre randomised controlled trial. The Lancet 2010; 375(9708): 31-40. doi:10.1016/S0140-6736(09)61755-4 Go to original source... Go to PubMed...




Vnitřní lékařství

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.